



HCV DRUG DEVELOPMENT ADVISORY GROUP MEETING #9

Nov 8, 2012 THE FENWAY INSTITUTE, BOSTON

www.hivforum.org



FORUM MISSION

- The Forum for Collaborative HIV Research is a public/private partnership including government agencies, industry, HIV researchers and clinicians, payors, foundations and the HIV patient advocacy community
- Our mission is to facilitate and enhance HIV research
- Apply HIV collaborative model to HCV





MEMBERS-PARTNERS-COLLABORATORS

Government Agencies

USA

- CDC
- FDA
- HHS/OASH
- HRSA
- NIH
 - NIAID
 - NIDA
 - NIMH
 - OAR
- OGAC
- USAID
- VA

Europe

- ANRS
- EMA

Academia / Providers

- ACTG
- INSIGHT
- Epi / Stats
- Immunology
- Virology
- Women's Health

Foundations

- BMGF
- amfAR
- EGPAF

Professional Societies

- AAN
- IAS
- HIVMA
- IDSA
- EASL
- AASLD

Industry

HIV

- Abbott Lab.
- Abbott Mol.
- Alere
- BD
- BI
- Bio-Rad
- BMS
- Genentech
- Gilead
- Illumina
- Janssen
- Merck
- Monogram
- Orasure
- PacBio
- Quest
- Quintiles
- Roche MS
- Tobira
- ViiV

HCV

- Abbott Lab.
- Abbott Mol.

HCV (cont.)

- Achillion
- Biocartis
- BI
- BMS
- DDL
- Genentech
- Gilead
- GSK
- Hoffman La Roche
- Idenix
- Janssen
- Merck
- Monogram
- Novartis
- PPD
- Quest
- Quintiles
- Roche MS
- Vertex
- Virco

Community / Advocacy

HIV

- ATAC
- CAB-ACTG
- CAB-INSIGHT
- EATG
- NGMAC
- TAG

HCV

- HCAB
- NATAP
- NVHR
- PWB+HCV
- TAG

Insurers

Kaiser Permanente



HCV DRUG DEVELOPMENT ADVISORY GROUP (HCV DRAG)

- Neutral, independent platform for dialogue among regulators (US, Europe), industry, professional societies, academia and community representatives in a rapidly evolving field
 - Clinical trial design for HCV DAA's in diverse populations
 - Standardization of nomenclature
 - Consensus on sequence analysis and phenotypic resistance studies
 - Collaborative network among HCV databases
 - Meet educational needs



HCV DRAG: STEERING COMMITTEE

enhancing & facilitating HIV research

- Robert Kaufmann
- Patrick Harrington
- Daria Hazuda
- Ira Jacobson
- Donald Jensen
- Filip Josephson
- Ann Kwong

- Jean-Michel Pawlotsky
- Nina Mani
- Veronica Miller
- Isabel Najera
- Stuart Ray
- Kimberly Struble
- Tracy Swan
- Heiner Wedemeyer





PROCESS

- Annual general meetings (x2)
 - EASL conference
 - AASLD conference
- Working group meetings (by phone) as needed
- Special topic meetings as needed





HCV DRAG WORKING GROUPS

- Sequence Analysis Working Group
- Phenotype Analysis Working Group
- Clinical Trials Working Group
- Definitions/Nomenclature Working Group
- Educational Slide Set Working Group
- Database Working Group



PRODUCTS & PUBLICATIONS

- Clinically relevant HCV drug resistance mutations figure and tables *Annals of the Forum for Collaborative HIV Research* 14(3): 1-8, Sep 12, 2012
- *Accepted* online 18 June 2012: Recommendations for standardized nomenclature and definitions of viral response in trials of HCV investigational agents –Special Article in *Hepatology*. DOI: 10.1002/hep.25888
- Poster: Consensus recommendations for virologic nomenclature in DAA clinical trials - Journal of Hepatology 56 (Suppl 2): S349, April 2012





PRODUCTS & PUBLICATIONS -2

- Submitted to Clinical Infectious Diseases:
 - Closing in on the Target: Sustained Virologic Response in Response-Guided Therapy

Manuscripts in process (draft in Program Book)

- Hepatitis C Drug Access for People with Inherited Bleeding Disorders
- Educational HCV Resistance Slide Set
 - Updated after each EASL/AASLD conference
 - Published on 5 websites
 - Managed by Erik Lontok



SUPPORT ACKNOWLEDGMENT

• The Forum receives funding from member pharmaceutical and diagnostic companies